A

AnaptysBio
D

ANAB

18.570
USD
-0.26
(-1.38%)
مغلق
حجم التداول
25,561
الربح لكل سهم
-6
العائد الربحي
-
P/E
-3
حجم السوق
565,060,625
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.350
    (-1.73%)
    19.940 USD
    ALNY
    ALNY
    -0.480
    (-0.19%)
    250.450 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    ESPR
    -0.03500
    (-1.88%)
    1.82500 USD
    N
    NBIX
    4.630
    (3.99%)
    120.710 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    S
    SRPT
    -2.010
    (-1.86%)
    106.280 USD
    V
    VKTX
    2.480
    (7.85%)
    34.090 USD
    المزيد
الأخبار
المقالات

العنوان: AnaptysBio

القطاع: Healthcare
الصناعة: Biotechnology
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA)and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).